Alnylam Pharmaceuticals (ALNY) Superinvestor holders
20 of the superinvestors we track hold Alnylam Pharmaceuticals (ALNY) in their latest 13F filings, $3.9B in total.
Summary
The largest holder is Baillie Gifford (Baillie Gifford & Co), with $1.4B, 1.3% of the portfolio.
In their latest quarter: 2 opened a new position, 5 added, 12 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Baillie Gifford Baillie Gifford & Co |
Added | 5,492,469 | $1.4B | 1.3% | Q3 2026 |
| Dodge & Cox | Added | 1,955,393 | $589M | 0.3% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Trimmed | 1,875,937 | $565M | 0.4% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Trimmed | 1,259,483 | $379M | 0.3% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 1,104,109 | $332M | 0.2% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 728,039 | $219M | 0.1% | Q2 2026 |
| Aziz Hamzaogullari Loomis Sayles & Co |
Added | 580,187 | $175M | 0.2% | Q2 2026 |
| Paul Marshall Marshall Wace |
Trimmed | 259,799 | $78M | 0.1% | Q2 2026 |
| Man Group Man Group plc |
Trimmed | 170,907 | $51M | 0.1% | Q2 2026 |
| Ray Dalio Bridgewater Associates |
Trimmed | 99,584 | $30M | 0.1% | Q2 2026 |
| Brett Barakett Tremblant Capital Group |
Trimmed | 92,940 | $28M | 0.8% | Q2 2026 |
| Arrowstreet Capital | New position | 49,601 | $15M | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 47,829 | $14M | 0.0% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | 42,051 | $13M | 0.0% | Q2 2026 |
| Alger Fred Alger Management |
Held | 12,597 | $4M | 0.0% | Q2 2026 |
| David Vogel Voloridge Investment Management |
Trimmed | 4,500 | $1M | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
Added | 4,758 | $1M | 0.0% | Q3 2026 |
| Ken Tropin Graham Capital Management |
New position | 2,256 | $679,124 | 0.0% | Q2 2026 |
| Murray Stahl Horizon Kinetics LLC |
Trimmed | 2,168 | $652,633 | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
Trimmed | 1,124 | $338,358 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 21 |
| Q1 2026 | 19 |
| Q4 2025 | 21 |
| Q3 2025 | 27 |
| Q2 2025 | 19 |
| Q1 2025 | 19 |
| Q4 2024 | 17 |
| Q3 2024 | 18 |
Questions about Alnylam Pharmaceuticals
Which superinvestors own Alnylam Pharmaceuticals?
20 of the superinvestors we track hold Alnylam Pharmaceuticals (ALNY) in their latest 13F filings, $3.9B in total. Baillie Gifford, Dodge & Cox, Two Sigma, Hersh Cohen, David Shaw, Cliff Asness.
Who is the largest superinvestor holder of ALNY?
The largest holder is Baillie Gifford (Baillie Gifford & Co), with $1.4B, 1.3% of the portfolio.
From Alnylam Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.